Retirement Systems of Alabama Sells 3,005 Shares of United Therapeutics Corporation $UTHR

Retirement Systems of Alabama lessened its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 3.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 97,268 shares of the biotechnology company’s stock after selling 3,005 shares during the quarter. Retirement Systems of Alabama’s holdings in United Therapeutics were worth $47,394,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. J. Safra Sarasin Holding AG increased its stake in shares of United Therapeutics by 8.6% in the fourth quarter. J. Safra Sarasin Holding AG now owns 630 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 50 shares in the last quarter. Northwest Wealth Management LLC bought a new position in United Therapeutics in the 4th quarter valued at $249,000. Spire Wealth Management bought a new position in shares of United Therapeutics in the fourth quarter worth $151,000. Terra Nova Asset Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $266,000. Finally, Kaufman Rossin Wealth LLC purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $258,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 12.5%

UTHR opened at $588.36 on Tuesday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $607.89. The stock has a market capitalization of $25.79 billion, a price-to-earnings ratio of 21.09, a PEG ratio of 1.88 and a beta of 0.84. The firm has a 50 day moving average price of $498.42 and a 200-day moving average price of $474.96.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $6.19 EPS. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Activity

In related news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,938,901.40. The trade was a 15.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $21,707,270.53. The trade was a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 333,820 shares of company stock valued at $165,495,478 in the last 90 days. Company insiders own 10.30% of the company’s stock.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 (Tyvaso) pivotal success — the 598‑patient Phase 3 trial met its primary endpoint, showing a Hodges‑Lehmann estimate of +130.1 mL change in absolute FVC at week 52 vs. placebo, a clinically meaningful result that expands Tyvaso’s potential market beyond PAH. Read More.
• Positive Sentiment: Ralinepag Phase 3 readout + buyback momentum — investors are still digesting positive ADVANCE OUTCOMES ralinepag data (large reduction in clinical‑worsening risk) and United Therapeutics’ board authorized up to $2B in buybacks with ~$1.5B in ASRs, which accelerates share‑count reduction and supports EPS. Read More.
• Positive Sentiment: Surge in call‑option activity — unusually large options flow (≈16,800 calls, ~789% above normal) signals bullish positioning and likely amplified intraday upside through speculative buying and short‑covering. (Market data entry)
• Positive Sentiment: Analyst lift — TD Cowen raised its price target to $660 and reiterated a Buy view, which likely reinforced investor conviction after the clinical news. Read More.
• Neutral Sentiment: Read‑through to peers — some smaller respiratory/rare‑disease names saw moves on trial read‑throughs and analyst notes (e.g., Insmed), but the competitive or regulatory implications for other firms remain speculative. Read More.
• Negative Sentiment: Insider selling — CEO Martine Rothblatt sold 9,500 shares on March 26, and public filings show extensive insider sales over recent months; while not unusual for a high‑value stock, heavy insider disposals can be perceived as a headwind by some investors. Read More.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $466.00 to $486.00 and gave the company an “equal weight” rating in a research report on Monday, March 23rd. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $557.64.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.